Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Aug 1, 2024
Finance
Venture Report: venBio closes new $528M fifth fund
Plus: Airna, ReviR, LTZ and Synthetica draw Series A cash, while Outpace, Confo and Healx refill their coffers
BioCentury | Jul 16, 2024
Deals
Deals report: Ipsen gets second ADC; Context buys MSLN
Plus: M&A deals by Lantheus, Illumina; and over half a dozen new partnerships
BioCentury | Mar 8, 2024
Product Development
Pfizer blends modality tools in new vision for oncology unit
Pharma outlines goals for oncology business as it moves to integrate ADC play Seagen
BioCentury | Dec 16, 2023
Finance
Dec. 15 Quick Takes: Pfizer, Nona in ADC deal
Plus: FDA approves Padcev/Keytruda for 1L advanced urothelial cancer, obesity play Fractyl files for IPO and updates from Merck, Syndax, AC Immune, BMS
BioCentury | Sep 27, 2023
Emerging Company Profile
Biotheus: fully-integrated mAb platform for optimized fast-follower products
China-based Biotheus goes from discovery to IND submission in about two years
BioCentury | Aug 25, 2023
Discovery & Translation
Denali’s brain delivery method; plus CAR T cell therapy combo and more
BioCentury’s roundup of translational innovations
BioCentury | Apr 21, 2023
Product Development
ADC advances at AACR: target diversity, optimizing internalization
BioCentury’s analysis of the AACR 2023 abstracts highlights innovation in antibody-drug conjugate design
BioCentury | Mar 7, 2023
Deals
March 6 Quick Takes: Adaptimmune acquiring TCR2 Therapeutics
Plus: BridgeBio gains on oral achondroplasia therapy data and updates from Esperion, Aclaris, Merck & Co., Voyager and more
BioCentury | Dec 20, 2022
Deals
Tmunity buyout gives next building block to Gilead’s Kite
Cell therapy business adds armored CAR T platform, handful of therapies, but won’t advance prostate cancer program
BioCentury | Nov 12, 2022
Product Development
Modalities merge into new platforms at SITC 2022
Meeting highlights new platforms combining pieces of cell therapy, bispecific, oncolytic virus and cytokine peptide technologies
Items per page:
1 - 10 of 157